{
    "info": {
        "nct_id": "NCT05588609",
        "official_title": "A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers",
        "inclusion_criteria": "(Groups A, B)\n\n1. Signed informed consent before initiation of any study procedures.\n2. Age ≥ 18 years at signature of informed consent.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n4. Estimated life expectancy of ≥ 12 weeks.\n5. Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multi-gated acquisition scan (MUGA).\n6. Adequate organ function:\n\n   * Absolute neutrophil count ≥ 1.5 × 109/L.\n   * Hemoglobin ≥ 9 g/dL.\n   * Platelets ≥ 100 × 109/L.\n   * Serum calcium within normal ranges (or corrected with supplements).\n   * Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN) (in case of liver involvement by malignancy, ALT/AST ≤ 5 × ULN will be allowed).\n   * Total bilirubin ≤ 1.5 × ULN (in case of Gilbert disease, total bilirubin ≤ 3 × ULN will be allowed).\n   * Estimated glomerular filtration rate of > 30 mL/min based on the Cockroft-Gault formula (Appendix D).\n   * Serum albumin > 3.0 g/dL.\n7. Availability of a representative tumor specimen, either a formalin-fixed paraffin embedded (FFPE) de novo (ie, obtained up to 2 months before signing of the informed consent form [ICF]) or an FFPE archival tumor sample, preferably collected within 2 years of the start of study treatment. A fresh FFPE sample is preferred.\n8. Sexually active male and female patients of childbearing potential must agree to use contraceptive measures.\n\nInclusion Criteria: (Group A Only)\n\nA1. Have histologically confirmed locally advanced, unresectable, or metastatic NSCLC harboring an NRG1 gene fusion detected by DNA- or RNA-based next generation sequencing in a tumor sample or in plasma-cell free DNA. A2. Have received prior standard therapy appropriate for the tumor type and disease or must be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy in the opinion of the Investigator or have no satisfactory available treatment options. A3. Have at least 1 measurable lesion per RECIST v1.1. A4. Able to swallow oral medications and absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption.\n\nInclusion Criteria: (Group B Only) B1. Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features. B2. Metastatic disease documented by at least 2 bone lesions on whole body bone scintigraphy, or soft tissue disease documented by computed tomography (CT) scan/magnetic resonance imaging (MRI). B3. Ongoing androgen deprivation with a serum testosterone level ≤ 1.73 nmol/L (≤ 50 ng/dL) at Screening. B4. Current ongoing therapy with a next-generation AR signaling inhibitor (enzalutamide or abiraterone) started at least 90 days before Screening. B5. Progressive disease by PCWG3 criteria B6. Able to swallow oral medications and absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "(Groups A, B)\n\n1. Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.\n2. Previous exposure to anti-HER3-directed therapies.\n3. Known leptomeningeal involvement.\n4. Participation in another interventional clinical trial or treatment with any investigational drug within 4 weeks before study entry.\n5. Chronic use of high-dose oral corticosteroid therapy (> 10 mg of prednisone- equivalent a day).\n6. Uncontrolled hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) or unstable angina.\n7. History of congestive heart failure Class II-IV by New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, or paroxysmal supraventricular tachycardia).\n8. History of myocardial infarction within 6 months of study entry.\n9. History of prior or concomitant malignancies (other than excised nonmelanoma skin cancer, cured in situ cervical carcinoma, or low-grade Ta or T1 urothelial carcinoma of the bladder that has undergone potentially curative therapy) within 3 years of study entry.\n10. Current serious illness or medical conditions including, but not limited to uncontrolled active infection, and clinically significant pulmonary, metabolic, or psychiatric disorders.\n11. Patients with the following known infectious diseases:\n\n    * Known active hepatitis B infection (hepatitis B surface antigen [HBsAg] positive) without receiving antiviral treatment.\n    * Known positive test for hepatitis C virus (HCV) RNA.\n12. Known human immunodeficiency virus (HIV)-positive patients unless the CD4+ count is ≥ 300/μL, viral load is undetectable, and the patient is currently receiving highly active antiretroviral therapy.\n\nExclusion Criteria: (Group A) A1. Patients previously exposed to afatinib. A2. History of interstitial lung disease (ILD), ILD-like adverse reactions (such as lung infiltration, pneumonitis, acute respiratory distress syndrome, allergic alveolitis), or radiation pneumonia requiring steroid therapy.\n\nExclusion Criteria: (Group B) B1. More than 2 lines of a second-generation hormonal agent for metastatic disease.\n\nB2. More than 2 lines of systemic chemotherapy for metastatic disease. B3. Patients with only nonmeasurable lesions other than bone metastasis (eg, pleural effusion, ascites, other visceral locations). B4. A history of seizure or any condition predisposing patient to seizure within 12 months before study treatment, including history of unexplained loss of consciousness or transient ischemic attack, for patients receiving enzalutamide.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Serum albumin > 3.0 g/dL.",
                "criterions": [
                    {
                        "exact_snippets": "Serum albumin > 3.0 g/dL",
                        "criterion": "serum albumin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3.0,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum albumin > 3.0 g/dL",
                        "criterion": "serum albumin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3.0,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Inclusion Criteria: (Group A Only)",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "8. Sexually active male and female patients of childbearing potential must agree to use contraceptive measures.",
                "criterions": [
                    {
                        "exact_snippets": "Sexually active male and female patients of childbearing potential must agree to use contraceptive measures.",
                        "criterion": "sexually active patients of childbearing potential",
                        "requirement": {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Sexually active male and female patients of childbearing potential must agree to use contraceptive measures.",
                        "criterion": "sexually active patients of childbearing potential",
                        "requirement": {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Total bilirubin ≤ 1.5 × ULN (in case of Gilbert disease, total bilirubin ≤ 3 × ULN will be allowed).",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 × ULN",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in case of Gilbert disease, total bilirubin ≤ 3 × ULN will be allowed",
                        "criterion": "total bilirubin in patients with Gilbert disease",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "in case of Gilbert disease, total bilirubin ≤ 3 × ULN will be allowed",
                    "criterion": "total bilirubin in patients with Gilbert disease",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": "<=",
                            "value": 3,
                            "unit": "ULN"
                        }
                    }
                },
                "then_criteria": null,
                "else_criteria": {
                    "exact_snippets": "Total bilirubin ≤ 1.5 × ULN",
                    "criterion": "total bilirubin",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": "<=",
                            "value": 1.5,
                            "unit": "ULN"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Estimated life expectancy of ≥ 12 weeks.",
                "criterions": [
                    {
                        "exact_snippets": "Estimated life expectancy of ≥ 12 weeks",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Estimated life expectancy of ≥ 12 weeks",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Estimated glomerular filtration rate of > 30 mL/min based on the Cockroft-Gault formula (Appendix D).",
                "criterions": [
                    {
                        "exact_snippets": "Estimated glomerular filtration rate of > 30 mL/min based on the Cockroft-Gault formula",
                        "criterion": "estimated glomerular filtration rate",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Estimated glomerular filtration rate of > 30 mL/min based on the Cockroft-Gault formula",
                        "criterion": "estimated glomerular filtration rate",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockroft-Gault formula"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Estimated glomerular filtration rate of > 30 mL/min based on the Cockroft-Gault formula",
                        "criterion": "estimated glomerular filtration rate",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Estimated glomerular filtration rate of > 30 mL/min based on the Cockroft-Gault formula",
                        "criterion": "estimated glomerular filtration rate",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockroft-Gault formula"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Signed informed consent before initiation of any study procedures.",
                "criterions": [
                    {
                        "exact_snippets": "Signed informed consent before initiation of any study procedures.",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Signed informed consent before initiation of any study procedures.",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "before initiation of any study procedures"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Signed informed consent before initiation of any study procedures.",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Signed informed consent before initiation of any study procedures.",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "before initiation of any study procedures"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Adequate organ function:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate organ function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Serum calcium within normal ranges (or corrected with supplements).",
                "criterions": [
                    {
                        "exact_snippets": "Serum calcium within normal ranges (or corrected with supplements)",
                        "criterion": "serum calcium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "within normal ranges"
                        }
                    },
                    {
                        "exact_snippets": "Serum calcium within normal ranges (or corrected with supplements)",
                        "criterion": "serum calcium",
                        "requirement": {
                            "requirement_type": "correction",
                            "expected_value": "corrected with supplements"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Serum calcium within normal ranges (or corrected with supplements)",
                        "criterion": "serum calcium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "within normal ranges"
                        }
                    },
                    {
                        "exact_snippets": "Serum calcium within normal ranges (or corrected with supplements)",
                        "criterion": "serum calcium",
                        "requirement": {
                            "requirement_type": "correction",
                            "expected_value": "corrected with supplements"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN) (in case of liver involvement by malignancy, ALT/AST ≤ 5 × ULN will be allowed).",
                "criterions": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 2.5 × upper limit of normal (ULN) (in case of liver involvement by malignancy, ALT ... ≤ 5 × ULN will be allowed)",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "aspartate aminotransferase (AST) ... ≤ 2.5 × upper limit of normal (ULN) (in case of liver involvement by malignancy, ... AST ≤ 5 × ULN will be allowed)",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "in case of liver involvement by malignancy, ALT/AST ≤ 5 × ULN will be allowed",
                        "criterion": "ALT and AST levels in case of liver involvement by malignancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "in case of liver involvement by malignancy, ALT/AST ≤ 5 × ULN will be allowed",
                    "criterion": "ALT and AST levels in case of liver involvement by malignancy",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 5,
                                    "unit": "ULN"
                                }
                            ]
                        }
                    }
                },
                "then_criteria": null,
                "else_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 2.5 × upper limit of normal (ULN) (in case of liver involvement by malignancy, ALT ... ≤ 5 × ULN will be allowed)",
                            "criterion": "alanine aminotransferase (ALT) level",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "comparisons": [
                                        {
                                            "operator": "<=",
                                            "value": 2.5,
                                            "unit": "ULN"
                                        }
                                    ]
                                }
                            }
                        },
                        {
                            "exact_snippets": "aspartate aminotransferase (AST) ... ≤ 2.5 × upper limit of normal (ULN) (in case of liver involvement by malignancy, ... AST ≤ 5 × ULN will be allowed)",
                            "criterion": "aspartate aminotransferase (AST) level",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "comparisons": [
                                        {
                                            "operator": "<=",
                                            "value": 2.5,
                                            "unit": "ULN"
                                        }
                                    ]
                                }
                            }
                        }
                    ]
                }
            }
        },
        {
            "identified_line": {
                "line": "* Absolute neutrophil count ≥ 1.5 × 109/L.",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count ≥ 1.5 × 10^9/L",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count ≥ 1.5 × 10^9/L",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelets ≥ 100 × 109/L.",
                "criterions": [
                    {
                        "exact_snippets": "Platelets ≥ 100 × 10^9/L.",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelets ≥ 100 × 10^9/L.",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Known active hepatitis B infection (hepatitis B surface antigen [HBsAg] positive) without receiving antiviral treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Known active hepatitis B infection (hepatitis B surface antigen [HBsAg] positive)",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "Known active hepatitis B infection (hepatitis B surface antigen [HBsAg] positive)",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "HBsAg status",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "without receiving antiviral treatment",
                        "criterion": "antiviral treatment for hepatitis B",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Known active hepatitis B infection (hepatitis B surface antigen [HBsAg] positive)",
                                "criterion": "hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": "active"
                                }
                            },
                            {
                                "exact_snippets": "Known active hepatitis B infection (hepatitis B surface antigen [HBsAg] positive)",
                                "criterion": "hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "HBsAg status",
                                    "expected_value": "positive"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "without receiving antiviral treatment",
                        "criterion": "antiviral treatment for hepatitis B",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Known positive test for hepatitis C virus (HCV) RNA.",
                "criterions": [
                    {
                        "exact_snippets": "Known positive test for hepatitis C virus (HCV) RNA",
                        "criterion": "hepatitis C virus (HCV) RNA test",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Known positive test for hepatitis C virus (HCV) RNA",
                        "criterion": "hepatitis C virus (HCV) RNA test",
                        "requirement": {
                            "requirement_type": "knowledge status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known positive test for hepatitis C virus (HCV) RNA",
                        "criterion": "hepatitis C virus (HCV) RNA test",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "Known positive test for hepatitis C virus (HCV) RNA",
                        "criterion": "hepatitis C virus (HCV) RNA test",
                        "requirement": {
                            "requirement_type": "knowledge status",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Exclusion Criteria: (Group A) A1. Patients previously exposed to afatinib. A2. History of interstitial lung disease (ILD), ILD-like adverse reactions (such as lung infiltration, pneumonitis, acute respiratory distress syndrome, allergic alveolitis), or radiation pneumonia requiring steroid therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Patients previously exposed to afatinib",
                        "criterion": "afatinib exposure",
                        "requirement": {
                            "requirement_type": "previous exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of interstitial lung disease (ILD)",
                        "criterion": "interstitial lung disease (ILD)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "ILD-like adverse reactions (such as lung infiltration, pneumonitis, acute respiratory distress syndrome, allergic alveolitis)",
                        "criterion": "ILD-like adverse reactions",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "radiation pneumonia requiring steroid therapy",
                        "criterion": "radiation pneumonia requiring steroid therapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Patients previously exposed to afatinib",
                                "criterion": "afatinib exposure",
                                "requirement": {
                                    "requirement_type": "previous exposure",
                                    "expected_value": true
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "History of interstitial lung disease (ILD)",
                                        "criterion": "interstitial lung disease (ILD)",
                                        "requirement": {
                                            "requirement_type": "history",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "ILD-like adverse reactions (such as lung infiltration, pneumonitis, acute respiratory distress syndrome, allergic alveolitis)",
                                        "criterion": "ILD-like adverse reactions",
                                        "requirement": {
                                            "requirement_type": "history",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "radiation pneumonia requiring steroid therapy",
                                        "criterion": "radiation pneumonia requiring steroid therapy",
                                        "requirement": {
                                            "requirement_type": "history",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Previous exposure to anti-HER3-directed therapies.",
                "criterions": [
                    {
                        "exact_snippets": "Previous exposure to anti-HER3-directed therapies",
                        "criterion": "exposure to anti-HER3-directed therapies",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Previous exposure to anti-HER3-directed therapies",
                    "criterion": "exposure to anti-HER3-directed therapies",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "10. Current serious illness or medical conditions including, but not limited to uncontrolled active infection, and clinically significant pulmonary, metabolic, or psychiatric disorders.",
                "criterions": [
                    {
                        "exact_snippets": "Current serious illness or medical conditions",
                        "criterion": "serious illness or medical conditions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled active infection",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "clinically significant pulmonary ... disorders",
                        "criterion": "pulmonary disorder",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant metabolic ... disorders",
                        "criterion": "metabolic disorder",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant ... psychiatric disorders",
                        "criterion": "psychiatric disorder",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Current serious illness or medical conditions",
                        "criterion": "serious illness or medical conditions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled active infection",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "clinically significant pulmonary ... disorders",
                        "criterion": "pulmonary disorder",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant metabolic ... disorders",
                        "criterion": "metabolic disorder",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant ... psychiatric disorders",
                        "criterion": "psychiatric disorder",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Known leptomeningeal involvement.",
                "criterions": [
                    {
                        "exact_snippets": "Known leptomeningeal involvement",
                        "criterion": "leptomeningeal involvement",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known leptomeningeal involvement",
                        "criterion": "leptomeningeal involvement",
                        "requirement": {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known leptomeningeal involvement",
                        "criterion": "leptomeningeal involvement",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known leptomeningeal involvement",
                        "criterion": "leptomeningeal involvement",
                        "requirement": {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Exclusion Criteria: (Group B) B1. More than 2 lines of a second-generation hormonal agent for metastatic disease.",
                "criterions": [
                    {
                        "exact_snippets": "More than 2 lines of a second-generation hormonal agent for metastatic disease",
                        "criterion": "lines of second-generation hormonal agent for metastatic disease",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "More than 2 lines of a second-generation hormonal agent for metastatic disease",
                        "criterion": "lines of second-generation hormonal agent for metastatic disease",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. History of myocardial infarction within 6 months of study entry.",
                "criterions": [
                    {
                        "exact_snippets": "History of myocardial infarction within 6 months of study entry.",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of myocardial infarction within 6 months of study entry.",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Patients with the following known infectious diseases:",
                "criterions": [
                    {
                        "exact_snippets": "Patients with the following known infectious diseases",
                        "criterion": "infectious diseases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with the following known infectious diseases",
                        "criterion": "infectious diseases",
                        "requirement": {
                            "requirement_type": "knowledge of diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients with the following known infectious diseases",
                        "criterion": "infectious diseases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with the following known infectious diseases",
                        "criterion": "infectious diseases",
                        "requirement": {
                            "requirement_type": "knowledge of diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Chronic use of high-dose oral corticosteroid therapy (> 10 mg of prednisone- equivalent a day).",
                "criterions": [
                    {
                        "exact_snippets": "Chronic use of high-dose oral corticosteroid therapy (> 10 mg of prednisone- equivalent a day)",
                        "criterion": "oral corticosteroid therapy",
                        "requirement": {
                            "requirement_type": "chronic use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Chronic use of high-dose oral corticosteroid therapy (> 10 mg of prednisone- equivalent a day)",
                        "criterion": "oral corticosteroid therapy",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg of prednisone-equivalent per day"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Chronic use of high-dose oral corticosteroid therapy (> 10 mg of prednisone- equivalent a day)",
                        "criterion": "oral corticosteroid therapy",
                        "requirement": {
                            "requirement_type": "chronic use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Chronic use of high-dose oral corticosteroid therapy (> 10 mg of prednisone- equivalent a day)",
                        "criterion": "oral corticosteroid therapy",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg of prednisone-equivalent per day"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.",
                "criterions": [
                    {
                        "exact_snippets": "Central nervous system metastases that are untreated",
                        "criterion": "central nervous system metastases",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    },
                    {
                        "exact_snippets": "Central nervous system metastases that are...symptomatic",
                        "criterion": "central nervous system metastases",
                        "requirement": {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    },
                    {
                        "exact_snippets": "Central nervous system metastases that...require radiation...to control symptoms within 14 days of study entry",
                        "criterion": "central nervous system metastases",
                        "requirement": {
                            "requirement_type": "need for radiation to control symptoms",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "within 14 days of study entry"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Central nervous system metastases that...require...surgery...to control symptoms within 14 days of study entry",
                        "criterion": "central nervous system metastases",
                        "requirement": {
                            "requirement_type": "need for surgery to control symptoms",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "within 14 days of study entry"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Central nervous system metastases that...require...continued steroid therapy to control symptoms within 14 days of study entry",
                        "criterion": "central nervous system metastases",
                        "requirement": {
                            "requirement_type": "need for continued steroid therapy to control symptoms",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "within 14 days of study entry"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Central nervous system metastases that are untreated",
                        "criterion": "central nervous system metastases",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    },
                    {
                        "exact_snippets": "Central nervous system metastases that are...symptomatic",
                        "criterion": "central nervous system metastases",
                        "requirement": {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    },
                    {
                        "exact_snippets": "Central nervous system metastases that...require radiation...to control symptoms within 14 days of study entry",
                        "criterion": "central nervous system metastases",
                        "requirement": {
                            "requirement_type": "need for radiation to control symptoms",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "within 14 days of study entry"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Central nervous system metastases that...require...surgery...to control symptoms within 14 days of study entry",
                        "criterion": "central nervous system metastases",
                        "requirement": {
                            "requirement_type": "need for surgery to control symptoms",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "within 14 days of study entry"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Central nervous system metastases that...require...continued steroid therapy to control symptoms within 14 days of study entry",
                        "criterion": "central nervous system metastases",
                        "requirement": {
                            "requirement_type": "need for continued steroid therapy to control symptoms",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "within 14 days of study entry"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "(Groups A, B)",
                "criterions": [
                    {
                        "exact_snippets": "(Groups A, B)",
                        "criterion": "study group assignment",
                        "requirement": {
                            "requirement_type": "group membership",
                            "expected_value": [
                                "A",
                                "B"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "7. Availability of a representative tumor specimen, either a formalin-fixed paraffin embedded (FFPE) de novo (ie, obtained up to 2 months before signing of the informed consent form [ICF]) or an FFPE archival tumor sample, preferably collected within 2 years of the start of study treatment. A fresh FFPE sample is preferred.",
                "criterions": [
                    {
                        "exact_snippets": "Availability of a representative tumor specimen",
                        "criterion": "tumor specimen",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "formalin-fixed paraffin embedded (FFPE) de novo (ie, obtained up to 2 months before signing of the informed consent form [ICF])",
                        "criterion": "FFPE de novo tumor specimen",
                        "requirement": {
                            "requirement_type": "collection_time_before_ICF",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "FFPE archival tumor sample, preferably collected within 2 years of the start of study treatment",
                        "criterion": "FFPE archival tumor sample",
                        "requirement": {
                            "requirement_type": "collection_time_before_study_treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "A fresh FFPE sample is preferred",
                        "criterion": "fresh FFPE sample",
                        "requirement": {
                            "requirement_type": "preference",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Availability of a representative tumor specimen",
                                "criterion": "tumor specimen",
                                "requirement": {
                                    "requirement_type": "availability",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "formalin-fixed paraffin embedded (FFPE) de novo (ie, obtained up to 2 months before signing of the informed consent form [ICF])",
                                "criterion": "FFPE de novo tumor specimen",
                                "requirement": {
                                    "requirement_type": "collection_time_before_ICF",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Availability of a representative tumor specimen",
                                "criterion": "tumor specimen",
                                "requirement": {
                                    "requirement_type": "availability",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "FFPE archival tumor sample, preferably collected within 2 years of the start of study treatment",
                                "criterion": "FFPE archival tumor sample",
                                "requirement": {
                                    "requirement_type": "collection_time_before_study_treatment",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "years"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Age ≥ 18 years at signature of informed consent.",
                "criterions": [
                    {
                        "exact_snippets": "Age ≥ 18 years at signature of informed consent.",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age  18 years at signature of informed consent.",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Hemoglobin ≥ 9 g/dL.",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin ≥ 9 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin \u0013e 9 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multi-gated acquisition scan (MUGA).",
                "criterions": [
                    {
                        "exact_snippets": "Left ventricular ejection fraction (LVEF) ≥ 50%",
                        "criterion": "left ventricular ejection fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Left ventricular ejection fraction (LVEF) ≥ 50%",
                        "criterion": "left ventricular ejection fraction (LVEF)",
                        "requirement": {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "echocardiogram (ECHO)",
                                "multi-gated acquisition scan (MUGA)"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "A1. Have histologically confirmed locally advanced, unresectable, or metastatic NSCLC harboring an NRG1 gene fusion detected by DNA- or RNA-based next generation sequencing in a tumor sample or in plasma-cell free DNA. A2. Have received prior standard therapy appropriate for the tumor type and disease or must be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy in the opinion of the Investigator or have no satisfactory available treatment options. A3. Have at least 1 measurable lesion per RECIST v1.1. A4. Able to swallow oral medications and absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption.",
                "criterions": [
                    {
                        "exact_snippets": "histologically confirmed locally advanced, unresectable, or metastatic NSCLC",
                        "criterion": "NSCLC disease status",
                        "requirement": {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "histologically confirmed locally advanced, unresectable, or metastatic NSCLC",
                        "criterion": "NSCLC disease status",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "harboring an NRG1 gene fusion detected by DNA- or RNA-based next generation sequencing in a tumor sample or in plasma-cell free DNA",
                        "criterion": "NRG1 gene fusion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "harboring an NRG1 gene fusion detected by DNA- or RNA-based next generation sequencing in a tumor sample or in plasma-cell free DNA",
                        "criterion": "NRG1 gene fusion",
                        "requirement": {
                            "requirement_type": "detection method",
                            "expected_value": [
                                "DNA-based next generation sequencing",
                                "RNA-based next generation sequencing"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "harboring an NRG1 gene fusion detected by DNA- or RNA-based next generation sequencing in a tumor sample or in plasma-cell free DNA",
                        "criterion": "NRG1 gene fusion",
                        "requirement": {
                            "requirement_type": "sample type",
                            "expected_value": [
                                "tumor sample",
                                "plasma-cell free DNA"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "received prior standard therapy appropriate for the tumor type and disease",
                        "criterion": "prior standard therapy",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy in the opinion of the Investigator",
                        "criterion": "tolerance or benefit from standard of care therapy",
                        "requirement": {
                            "requirement_type": "tolerance or benefit",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "have no satisfactory available treatment options",
                        "criterion": "satisfactory available treatment options",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "at least 1 measurable lesion per RECIST v1.1",
                        "criterion": "measurable lesion (RECIST v1.1)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Able to swallow oral medications",
                        "criterion": "ability to swallow oral medications",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption",
                        "criterion": "gastrointestinal conditions affecting absorption",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "Inclusion Criteria: (Group B Only) B1. Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features. B2. Metastatic disease documented by at least 2 bone lesions on whole body bone scintigraphy, or soft tissue disease documented by computed tomography (CT) scan/magnetic resonance imaging (MRI). B3. Ongoing androgen deprivation with a serum testosterone level ≤ 1.73 nmol/L (≤ 50 ng/dL) at Screening. B4. Current ongoing therapy with a next-generation AR signaling inhibitor (enzalutamide or abiraterone) started at least 90 days before Screening. B5. Progressive disease by PCWG3 criteria B6. Able to swallow oral medications and absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption.",
                "criterions": [
                    {
                        "exact_snippets": "Histologically confirmed adenocarcinoma of the prostate",
                        "criterion": "adenocarcinoma of the prostate",
                        "requirement": {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "without neuroendocrine differentiation or small cell features",
                        "criterion": "neuroendocrine differentiation or small cell features",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Metastatic disease documented by at least 2 bone lesions on whole body bone scintigraphy",
                        "criterion": "bone lesions (metastatic disease)",
                        "requirement": {
                            "requirement_type": "number of lesions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lesions"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Metastatic disease documented by at least 2 bone lesions on whole body bone scintigraphy",
                        "criterion": "bone lesions (metastatic disease)",
                        "requirement": {
                            "requirement_type": "documentation method",
                            "expected_value": "whole body bone scintigraphy"
                        }
                    },
                    {
                        "exact_snippets": "soft tissue disease documented by computed tomography (CT) scan/magnetic resonance imaging (MRI)",
                        "criterion": "soft tissue disease (metastatic)",
                        "requirement": {
                            "requirement_type": "documentation method",
                            "expected_value": [
                                "computed tomography (CT) scan",
                                "magnetic resonance imaging (MRI)"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Ongoing androgen deprivation with a serum testosterone level ≤ 1.73 nmol/L (≤ 50 ng/dL) at Screening",
                        "criterion": "serum testosterone level",
                        "requirement": {
                            "requirement_type": "value at Screening",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.73,
                                "unit": "nmol/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Ongoing androgen deprivation with a serum testosterone level ≤ 1.73 nmol/L (≤ 50 ng/dL) at Screening",
                        "criterion": "serum testosterone level",
                        "requirement": {
                            "requirement_type": "androgen deprivation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current ongoing therapy with a next-generation AR signaling inhibitor (enzalutamide or abiraterone) started at least 90 days before Screening",
                        "criterion": "next-generation AR signaling inhibitor therapy",
                        "requirement": {
                            "requirement_type": "current therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Current ongoing therapy with a next-generation AR signaling inhibitor (enzalutamide or abiraterone) started at least 90 days before Screening",
                        "criterion": "next-generation AR signaling inhibitor therapy",
                        "requirement": {
                            "requirement_type": "duration before Screening",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Current ongoing therapy with a next-generation AR signaling inhibitor (enzalutamide or abiraterone) started at least 90 days before Screening",
                        "criterion": "next-generation AR signaling inhibitor therapy",
                        "requirement": {
                            "requirement_type": "drug",
                            "expected_value": [
                                "enzalutamide",
                                "abiraterone"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Progressive disease by PCWG3 criteria",
                        "criterion": "progressive disease",
                        "requirement": {
                            "requirement_type": "PCWG3 criteria",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Able to swallow oral medications",
                        "criterion": "ability to swallow oral medications",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption",
                        "criterion": "gastrointestinal conditions jeopardizing intestinal absorption",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "9. History of prior or concomitant malignancies (other than excised nonmelanoma skin cancer, cured in situ cervical carcinoma, or low-grade Ta or T1 urothelial carcinoma of the bladder that has undergone potentially curative therapy) within 3 years of study entry.",
                "criterions": [
                    {
                        "exact_snippets": "History of prior or concomitant malignancies (other than excised nonmelanoma skin cancer, cured in situ cervical carcinoma, or low-grade Ta or T1 urothelial carcinoma of the bladder that has undergone potentially curative therapy) within 3 years of study entry.",
                        "criterion": "prior or concomitant malignancies",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of prior or concomitant malignancies (other than excised nonmelanoma skin cancer, cured in situ cervical carcinoma, or low-grade Ta or T1 urothelial carcinoma of the bladder that has undergone potentially curative therapy) within 3 years of study entry.",
                        "criterion": "prior or concomitant malignancies",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "malignancy"
                        }
                    },
                    {
                        "exact_snippets": "History of prior or concomitant malignancies (other than excised nonmelanoma skin cancer, cured in situ cervical carcinoma, or low-grade Ta or T1 urothelial carcinoma of the bladder that has undergone potentially curative therapy) within 3 years of study entry.",
                        "criterion": "prior or concomitant malignancies",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "excised nonmelanoma skin cancer",
                                "cured in situ cervical carcinoma",
                                "low-grade Ta or T1 urothelial carcinoma of the bladder that has undergone potentially curative therapy"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "History of prior or concomitant malignancies (other than excised nonmelanoma skin cancer, cured in situ cervical carcinoma, or low-grade Ta or T1 urothelial carcinoma of the bladder that has undergone potentially curative therapy) within 3 years of study entry.",
                        "criterion": "prior or concomitant malignancies",
                        "requirement": {
                            "requirement_type": "time since diagnosis or treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "7. History of congestive heart failure Class II-IV by New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, or paroxysmal supraventricular tachycardia).",
                "criterions": [
                    {
                        "exact_snippets": "History of congestive heart failure Class II-IV by New York Heart Association criteria",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of congestive heart failure Class II-IV by New York Heart Association criteria",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "NYHA class"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "NYHA class"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "serious cardiac arrhythmia requiring treatment (except atrial fibrillation, or paroxysmal supraventricular tachycardia)",
                        "criterion": "serious cardiac arrhythmia",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "serious cardiac arrhythmia requiring treatment (except atrial fibrillation, or paroxysmal supraventricular tachycardia)",
                        "criterion": "serious cardiac arrhythmia",
                        "requirement": {
                            "requirement_type": "arrhythmia type exclusion",
                            "expected_value": [
                                "atrial fibrillation",
                                "paroxysmal supraventricular tachycardia"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "(Groups A, B)",
                "criterions": [
                    {
                        "exact_snippets": "(Groups A, B)",
                        "criterion": "study group assignment",
                        "requirement": {
                            "requirement_type": "group membership",
                            "expected_value": [
                                "A",
                                "B"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "6. Uncontrolled hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) or unstable angina.",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "systolic blood pressure > 150 mmHg",
                        "criterion": "systolic blood pressure",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 150,
                                "unit": "mmHg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "diastolic blood pressure > 100 mmHg",
                        "criterion": "diastolic blood pressure",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mmHg"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unstable angina",
                        "criterion": "angina",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)",
                                "criterion": "hypertension",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": "uncontrolled"
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "systolic blood pressure > 150 mmHg",
                                        "criterion": "systolic blood pressure",
                                        "requirement": {
                                            "requirement_type": "value",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 150,
                                                "unit": "mmHg"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "diastolic blood pressure > 100 mmHg",
                                        "criterion": "diastolic blood pressure",
                                        "requirement": {
                                            "requirement_type": "value",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 100,
                                                "unit": "mmHg"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "exact_snippets": "unstable angina",
                        "criterion": "angina",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Participation in another interventional clinical trial or treatment with any investigational drug within 4 weeks before study entry.",
                "criterions": [
                    {
                        "exact_snippets": "Participation in another interventional clinical trial",
                        "criterion": "participation in another interventional clinical trial",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "treatment with any investigational drug within 4 weeks before study entry",
                        "criterion": "treatment with investigational drug",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "treatment with any investigational drug within 4 weeks before study entry",
                        "criterion": "treatment with investigational drug",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Participation in another interventional clinical trial",
                        "criterion": "participation in another interventional clinical trial",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "treatment with any investigational drug within 4 weeks before study entry",
                                "criterion": "treatment with investigational drug",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "treatment with any investigational drug within 4 weeks before study entry",
                                "criterion": "treatment with investigational drug",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "B2. More than 2 lines of systemic chemotherapy for metastatic disease. B3. Patients with only nonmeasurable lesions other than bone metastasis (eg, pleural effusion, ascites, other visceral locations). B4. A history of seizure or any condition predisposing patient to seizure within 12 months before study treatment, including history of unexplained loss of consciousness or transient ischemic attack, for patients receiving enzalutamide.",
                "criterions": [
                    {
                        "exact_snippets": "More than 2 lines of systemic chemotherapy for metastatic disease",
                        "criterion": "lines of systemic chemotherapy for metastatic disease",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients with only nonmeasurable lesions other than bone metastasis (eg, pleural effusion, ascites, other visceral locations)",
                        "criterion": "nonmeasurable lesions (excluding bone metastasis)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with only nonmeasurable lesions other than bone metastasis (eg, pleural effusion, ascites, other visceral locations)",
                        "criterion": "nonmeasurable lesions (excluding bone metastasis)",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": [
                                "pleural effusion",
                                "ascites",
                                "other visceral locations"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "A history of seizure or any condition predisposing patient to seizure within 12 months before study treatment, including history of unexplained loss of consciousness or transient ischemic attack, for patients receiving enzalutamide",
                        "criterion": "history of seizure or condition predisposing to seizure",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "A history of seizure or any condition predisposing patient to seizure within 12 months before study treatment, including history of unexplained loss of consciousness or transient ischemic attack, for patients receiving enzalutamide",
                        "criterion": "history of seizure or condition predisposing to seizure",
                        "requirement": {
                            "requirement_type": "predisposing_condition",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A history of seizure or any condition predisposing patient to seizure within 12 months before study treatment, including history of unexplained loss of consciousness or transient ischemic attack, for patients receiving enzalutamide",
                        "criterion": "history of seizure or condition predisposing to seizure",
                        "requirement": {
                            "requirement_type": "receiving_enzalutamide",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of unexplained loss of consciousness or transient ischemic attack, for patients receiving enzalutamide",
                        "criterion": "history of unexplained loss of consciousness or transient ischemic attack",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "history of unexplained loss of consciousness or transient ischemic attack, for patients receiving enzalutamide",
                        "criterion": "history of unexplained loss of consciousness or transient ischemic attack",
                        "requirement": {
                            "requirement_type": "receiving_enzalutamide",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "12. Known human immunodeficiency virus (HIV)-positive patients unless the CD4+ count is ≥ 300/μL, viral load is undetectable, and the patient is currently receiving highly active antiretroviral therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Known human immunodeficiency virus (HIV)-positive patients",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "CD4+ count is ≥ 300/μL",
                        "criterion": "CD4+ count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 300,
                                "unit": "μL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "viral load is undetectable",
                        "criterion": "HIV viral load",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        }
                    },
                    {
                        "exact_snippets": "currently receiving highly active antiretroviral therapy",
                        "criterion": "highly active antiretroviral therapy (HAART)",
                        "requirement": {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "Known human immunodeficiency virus (HIV)-positive patients",
                    "criterion": "HIV status",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "not_criteria": {
                        "and_criteria": [
                            {
                                "exact_snippets": "CD4+ count is  300/\u0003bcL",
                                "criterion": "CD4+ count",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 300,
                                        "unit": "\u0003bcL"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "viral load is undetectable",
                                "criterion": "HIV viral load",
                                "requirement": {
                                    "requirement_type": "detectability",
                                    "expected_value": "undetectable"
                                }
                            },
                            {
                                "exact_snippets": "currently receiving highly active antiretroviral therapy",
                                "criterion": "highly active antiretroviral therapy (HAART)",
                                "requirement": {
                                    "requirement_type": "current treatment",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                },
                "else_criteria": null
            }
        }
    ],
    "failed_miscellaneous": []
}